NetworkNewsBreaks – Zenosense, Inc. (ZENO) Aims

NetworkNewsBreaks – Zenosense, Inc. (ZENO) Aims to Provide First Responders with Handheld Diagnostic Device for Cardiac Emergency

Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing MIDS Cardiac™ to give first responders a rapid, highly sensitive analysis of heart biomarkers. An article discussing the company reads: “This handheld device aims to deliver accuracy equal or superior to these ‘gold standard’ central laboratory analyzers at the POC – taking lab testing to the patient. MIDS Cardiac aims to deliver high sensitivity results that are available within minutes. This would provide first responders with a new level of point of care device analysis. It will save valuable time during the so-called ‘golden hour’, when critical treatment is crucial to positive outcomes, and could also quickly rule out the majority of patients presenting with chest pain who are not suffering a heart attack, resulting in enormous hospital savings.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer